Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00617799 · ClinicalTrials.gov registry record
Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma
A clinical trial, sponsored by University of Nebraska.
- Completed
- Registry status
- 15
- Enrollment target
NCT00617799: Completed study, sponsored by University of Nebraska.
NCT00617799 is a clinical trial that has completed, run by University of Nebraska. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00617799 has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- 15 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at biomarkers that predict response to high-dose aldesleukin in patients with metastatic kidney cancer or metastatic melanoma.
Primary Outcome
Relationship of peripheral blood lymphocyte phenotype to response to high-dose aldesleukin (IL-2) from blood draws at baseline, prior to course 2 and 4 weeks after course 2
Interventions
- GENETIC gene expression analysis
- GENETIC mutation analysis
- OTHER flow cytometry
- BIOLOGICAL aldesleukin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2007-10-02 |
| Est. Completion | 2010-04-16 |
What the finished NCT00617799 record still lists
NCT00617799 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 15 participants, a relatively small participant target.
The record links to 0 conditions, and to 4 interventions - of which gene expression analysis is the first listed.
NCT00617799 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00617799 about?
NCT00617799 is a clinical study titled "Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma". RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at...
What is the current status of trial NCT00617799?
This trial is currently completed. The enrollment target is 15 participants. The study started on 2007-10-02. Estimated completion is 2010-04-16.
What interventions are being tested in trial NCT00617799?
The interventions under investigation include: gene expression analysis (GENETIC), mutation analysis (GENETIC), flow cytometry (OTHER), aldesleukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00617799?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI